Teva’s ProAir HFA (albuterol sulfate inhalation aerosol) is now approved for the treatment and prevention of bronchospasm in children 4–11 years of age.
ProAir HFA has already been available for the treatment or prevention of bronchospasm in reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients ≥12 years of age.
For more information call (888) 482-9522 or visit www.ProAirHFA.com.
Related Content
-
Share on Facebook
-
Share on Twitter
-
Share on LinkedIn
-
Share by Email
-
Print
